TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07579949: A Phase 2 Study to Determine the Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of SNH-119014 in Adult Subjects With Non-transfusion-dependent Thalassemia

Sponsor: ScinnoHub Pharmaceutical Co., Ltd. · Phase: PHASE2 · Area: CARDIOLOGY_METABOLIC · Target Enrollment: 30 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$3,087,600

Rescue Site Savings

+$2,025,200

Unlock Full NCT07579949 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07579949 Rescue Dossier →